The Phenylalanine Hydroxylase Gene Locus-Specific Database and BIOPKU are public databases used to track genotypes in hyperphenylalaninemia. However, the rapidly expanding databases and evolving nomenclature standards require a comprehensive characterization of the current variant landscape. We performed a descriptive statistical analysis of PAH variant allocations, allele frequencies (AF%), and phenotypic annotations using PAHvdb database. Over the period 2022–2026, the PAHvdb expanded by 169.26%. Of the 3409 variants studied, 75.68% of the phenotypes were not assigned. Splicing-related mutations comprised approximately 4.37% of the database, with classic phenylketonuria phenotypes represented in both donor–acceptor and splice-region categories. Only 3.84% of the variants had enzymatic activity (EA%) data, which offer the most direct biochemical evidence for genotype–phenotype inference. The strong Spearman’s rank correlation coefficient (ρ) between EA% and APV (ρ = 0.745, p < 0.001) was consistent with the established relationship between residual PAH EA% and the severity of metabolic phenotype. The AF% distribution was markedly asymmetric and dominated by a small number of alleles that were most frequently reported in the database. These findings highlight the increasing clinical reliance on these databases. Our analysis highlights a heterogeneity of rare, uncharacterized variants of uncertain significance and underscores the need for unified, systematic reviews to standardize nomenclature and resolve phenotype–genotype discrepancies.
No takes yet. Share an insight, caveat, or question.
Амиргазин et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: